Dominican Republic vs Kyrgyzstan: Average cost of multi drug-resistant tuberculosis treatment
Dominican Republic
1,650 constant 2022 US$
in 2024
Kyrgyzstan
1,607 constant 2022 US$
in 2022
Dominican Republic rank
28th
Kyrgyzstan rank
29th
Average cost of multi drug-resistant tuberculosis treatment over time
- Dominican Republic
- Kyrgyzstan
How they compare
Dominican Republic currently reports 1,650 constant 2022 US$ against 1,607 constant 2022 US$ in Kyrgyzstan, a difference of 43 constant 2022 US$.
The two have swapped places 3 times across 6 shared years of data; in 2017 it was Kyrgyzstan ahead.
Dominican Republic ranks 28th and Kyrgyzstan ranks 29th of 92 countries.
Across the 2 decades both report, Dominican Republic averaged higher in 1 and Kyrgyzstan in 1.
Head to head by decade
| Decade | Dominican Republic | Kyrgyzstan | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 1,951 constant 2022 US$ | 2,218 constant 2022 US$ | 267 constant 2022 US$ | Kyrgyzstan |
| 2020s | 1,966 constant 2022 US$ | 1,761 constant 2022 US$ | 205.33 constant 2022 US$ | Dominican Republic |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher average cost of multi drug-resistant tuberculosis treatment, Dominican Republic or Kyrgyzstan?
- Dominican Republic, at 1,650 constant 2022 US$ against 1,607 constant 2022 US$ in Kyrgyzstan as of 2024.
- What is the difference in average cost of multi drug-resistant tuberculosis treatment between Dominican Republic and Kyrgyzstan?
- 43 constant 2022 US$, with Dominican Republic ahead.
- How many years of comparable data are there for Dominican Republic and Kyrgyzstan?
- 6 years are reported by both, from 2017 to 2022.
- How do Dominican Republic and Kyrgyzstan rank globally for average cost of multi drug-resistant tuberculosis treatment?
- Dominican Republic ranks 28th and Kyrgyzstan ranks 29th of 92 countries.
- Where does this data come from?
- WHO (2025) – with minor processing by Our World in Data, published as Average cost of multi drug-resistant tuberculosis treatment. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Average cost of drugs spent per patient starting multidrug-resistant tuberculosis treatment, excluding buffer stock.